The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration
暂无分享,去创建一个
Tomasz Anyszek | Andrzej Panek | Agnieszka Chojęta | E. Martin | Anna Piotrowska-Mietelska | J. Swadźba
[1] Isaac Yeboah Addo,et al. Duration of immunity following full vaccination against SARS-CoV-2: a systematic review , 2022, Archives of Public Health.
[2] J. Fallon,et al. Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months , 2022, Vaccines.
[3] I. Drexler,et al. Adjusted booster schedules disperse age-dependent differences in antibody titers benefitting risk populations - Update to: Age-dependent Immune Response to the BioNTech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination , 2022, medRxiv.
[4] M. Neagu,et al. Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers , 2022, Scientific Reports.
[5] F. Carrat,et al. Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients , 2022, Scientific Reports.
[6] N. Lee,et al. Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination , 2022, Vaccines.
[7] S. Ruță,et al. Assessment of the Humoral Immune Response Following COVID-19 Vaccination in Healthcare Workers: A One Year Longitudinal Study , 2022, Biomedicines.
[8] J. Swadzba,et al. Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course , 2022, Diagnostics.
[9] S. Čučnik,et al. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals , 2022, Frontiers in Immunology.
[10] G. Lippi,et al. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals , 2022, Clinical chemistry and laboratory medicine.
[11] R. Middleton,et al. Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre , 2022, PloS one.
[12] A. Giuliano,et al. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida , 2022, JAMA oncology.
[13] William F. Fadel,et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[14] A. Pekosz,et al. Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine , 2022, medRxiv.
[15] A. Monto. The Future of SARS-CoV-2 Vaccination - Lessons from Influenza. , 2021, The New England journal of medicine.
[16] M. Gisslén,et al. Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses , 2021, Frontiers in Immunology.
[17] Tomasz Anyszek,et al. Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination , 2021, Vaccines.
[18] A. Milstone,et al. Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. , 2021, JAMA.
[19] C. Di Resta,et al. Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine , 2021, Vaccines.
[20] M. Hernán,et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.
[21] M. Plebani,et al. SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays , 2021, Clinica Chimica Acta.
[22] M. Nussenzweig,et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape , 2021, Nature.
[23] Michael I. Mandel,et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.
[24] L. Tserel,et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study , 2021, The Lancet Regional Health - Europe.
[25] M. Vekemans,et al. Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary , 2021, The Journal of Infection.
[26] M. Vekemans,et al. Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected , 2021, Journal of Infection.
[27] B. Mizrahi,et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine , 2021, Nature Communications.
[28] U. Liebert,et al. The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe , 2021, COVID.
[29] J. Vekemans,et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[30] M. Vidali,et al. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine , 2021, Diagnostics.
[31] C. von Kalle,et al. Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany , 2021, Emerging infectious diseases.
[32] G. Lippi,et al. Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How? , 2021, Diagnostics.
[33] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[34] G. Lippi,et al. Anti-SARS-CoV-2 Receptor Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination , 2021, SSRN Electronic Journal.
[35] H. Schaal,et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination , 2021, medRxiv.
[36] D. Stuart,et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.
[37] M. V. van Zelm,et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence , 2020, Science Immunology.
[38] M. Malim,et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.
[39] Mei San Tang,et al. Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays , 2020, bioRxiv.
[40] N. Basta,et al. Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2 , 2020, Annals of Internal Medicine.
[41] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[42] R. Evans. European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).